Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Cue Biopharma (CUE) Interest & Investment Income (2018 - 2025)

Cue Biopharma (CUE) has disclosed Interest & Investment Income for 8 consecutive years, with $158000.0 as the latest value for Q4 2025.

  • Quarterly Interest & Investment Income fell 45.52% to $158000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $748000.0 through Dec 2025, down 53.88% year-over-year, with the annual reading at $807000.0 for FY2025, 50.25% down from the prior year.
  • Interest & Investment Income hit $158000.0 in Q4 2025 for Cue Biopharma, down from $222000.0 in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $905000.0 in Q4 2023 to a low of $3898.0 in Q4 2021.
  • Historically, Interest & Investment Income has averaged $308694.9 across 5 years, with a median of $211000.0 in 2022.
  • Biggest five-year swings in Interest & Investment Income: plummeted 95.0% in 2021 and later skyrocketed 16113.44% in 2022.
  • Year by year, Interest & Investment Income stood at $3898.0 in 2021, then surged by 16113.44% to $632000.0 in 2022, then skyrocketed by 43.2% to $905000.0 in 2023, then crashed by 67.96% to $290000.0 in 2024, then crashed by 45.52% to $158000.0 in 2025.
  • Business Quant data shows Interest & Investment Income for CUE at $158000.0 in Q4 2025, $222000.0 in Q3 2025, and $198000.0 in Q2 2025.